Clinical safety of induced CTL infusion through recombinant adeno-associated virus-transfected dendritic cell vaccination in Chinese cancer patients

Clinical and Translational Oncology

Volumn 14, Issue 9, 2012, Pages 675-681

  Di, Lijun ^a   Zhu, Yulin ^a   Jia, Jun ^a   Yu, Jing ^a   Song, Gonghong ^a   Zhang, Jie ^a   Che, Li ^a   Yang, Huabing ^a   Han, Yan ^a   Ma, Bo ^a   Zhang, Chunrong ^a   Yuan, Yanhua ^a   You, Miaoning ^a   Wan, Fengling ^a   Wang, Xiaoli ^a   Zhou, Xinna ^a   Ren, Jun ^a,b  

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Cytotoxic T lymphocyte; Immunotherapy; RAAV DC

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; COMPLEMENTARY DNA; DENDRITIC CELL VACCINE; PARVOVIRUS VECTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; ADVANCED CANCER; AGED; ANTIGEN EXPRESSION; ARTICLE; BILE DUCT CARCINOMA; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE INFUSION; DRUG FEVER; EX VIVO STUDY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LUNG CANCER; MALE; PHENOTYPE; STOMACH CANCER; UTERINE CERVIX CANCER; VIRAL GENE DELIVERY SYSTEM;

ADULT; AGED; CANCER VACCINES; DENDRITIC CELLS; DEPENDOVIRUS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; MALE; MIDDLE AGED; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION;

EID: 84871194317     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-012-0854-7     Document Type: Article

References (30)

1. Dougan M, Dranoff G (2009) Immune therapy for cancer. Annu Rev Immunol 27:83-117
2. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME (2008) Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 8(4):299-308
3. Aruga A, Yamauchi K, Takasaki K, Furukawa T, Hanyu F (1991) Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. Int J Cancer 49(1):19-24
4. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T (2000) Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232):807-820
5. Melief CJ (2008) Cancer immunotherapy by dendritic cells. Immunity 29(3):372-383
6. Aarntzen EH, Figdor CG, Adema GJ, Punt CJ, de Vries IJ (2008) Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 57(10):1559-1568
7. Decker WK, Xing D, Shpall EJ (2006) Dendritic cell immunotherapy for the treatment of neoplastic disease. Biol Blood Marrow Transpl 12(2):113-125
8. Tuyaerts S, Aerts JL, Corthals J, Neyns B, Heirman C, Breckpot K, Thielemans K, Bonehill A (2007) Current approaches in dendritic cell generation implications for cancer immunotherapy. Cancer Immunol Immunother 56(10):1513-1537
9. Schuler-Thurner B, Schultz ES, Berger TG, Weinlich G, Ebner S, Woerl P, Bender A, Feuerstein B, Fritsch PO, Romani N, Schuler G (2002) Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J Exp Med 195(10):1279-1288
10. Höltl L, Zelle-Rieser C, Gander H, Papesh C, Ramoner R, Bartsch G, Rogatsch H, Barsoum AL, Coggin JH Jr, Thurnher M (2002) Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin Cancer Res 8(11):3369-3376
11. Fong L, Brockstedt D, Benike C, Breen JK, Strang G, Ruegg CL, Engleman EG (2001) Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J Immunol 167(12):7150-7156
12. Ladhams A, Schmidt C, Sing G, Butterworth L, Fielding G, Tesar P, Strong R, Leggett B, Powell L, Maddern G, Ellem K, Cooksley G (2002) Treatment of non-resectable hepatocellular carcinoma with autologous tumor-pulsed dendritic cells. J Gastroenterol Hepatol 17(8):889-896
13. Maier T, Tun-Kyi A, Tassis A, Jungius KP, Burg G, Dummer R, Nestle FO (2003) Vaccination of patients with cutaneous T-cell lymphoma using intran-odal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102(7):2338-2344
14. Zhang L, Zhang H, Liu W, Wang H, Jia J, Si X, Ren J (2005) Specific anti-hepatocellular carcinoma T cells generated by dendritic cells pulsed with hepatocellular carcinoma cell line HepG2 total RNA. Cell Immunol 238(1):61-66
15. Zhang HM, Zhang LW, Ren J, Fan L, Si XM, Liu WC (2006) Induction of alpha-fetoprotein-specific CD4-and CD8-mediated T-cell response using RNA-transfected dendritic cells. Cell Immunol 239(2):144-150
16. Zhang HM, Zhang LW, Liu WC, Cheng J, Si XM, Ren J (2006) Comparative analysis of DC fused with tumor cells or transfected with tumor total RNA as potential cancer vaccines against hepatocellular carcinoma. Cytotherapy 8(6):580-588
17. Yang JY, Cao DY, Liu WC, Zhang HM, Teng ZH, Ren J (2006) Dendritic cell generated from CD34? hematopoietic progenitors can be transfected with adenovirus containing gene of HBsAg and induce antigen-specific cytotoxic T cell responses. Cell Immunol 240(1):14-21
18. Ren J, Jia J, Zhang H, Zhang L, Ma B, Jiang H, Di L, Song G, Yu J (2008) Dendritic cells pulsed with alpha-fetoprotein and mutant P53 fused gene induce bi-targeted cytotoxic T lymphocyte response against hepatic carcinoma. Cancer Sci 99(7):1420-1426
19. Daya S, Berns KI (2008) Gene therapy using adeno-associated virus vectors. Clin Microbiol Rev 21(4):583-593
20. Robert-Guroff M (2007) Replicating and non-replicating viral vectors for vaccine development. Curr Opin Biotechnol 18(6):546-556
21. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, Bland RJ, Young D, Strybing K, Eidelberg D, During MJ (2007) Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369(9579):2097-2105
22. Mahadevan M, Liu Y, You C, Luo R, You H, Mehta JL, Hermonat PL (2007) Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associ-ated virus. Cancer Immunol Immunother 56(10):1615-1624
23. Chiriva-Internati M, Liu Y, Weidanz JA, Grizzi F, You H, Zhou W, Bumm K, Barlogie B, Mehta JL, Hermonat PL (2003) Testing recombinant adeno-asso-ciated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 102(9):3100-3107
24. Dudley ME, Rosenberg SA (2007) Adoptive cell transfer therapy. Semin Oncol 34(6):524-531
25. June CH (2007) Adoptive T cell therapy for cancer in the clinic. J Clin Invest 117(6):1466-1476
26. Banchereau J, Steinman RM (1998) Dendritic cells and the control of immunity. Nature 392(6673):245-252
27. Figdor CG, de Vries IJ, Lesterhuis WJ, Melief CJ (2004) Dendritic cell immunotherapy: mapping the way. Nat Med 10(5):475-480
28. Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee C (2004) Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther 9(5):757-764
29. Oh ST, Kim CH, Park MY, Won EH, Sohn HJ, Cho HI, Kang WK, Hong YK, Kim TG (2006) Dendritic cells transduced with recombinant adenoviruses induce more efficient anti-tumor immunity than dendritic cells pulsed with peptide. Vaccine 24(15):2860-2868
30. Steinman RM (2007) Dendritic cells: understanding immunogenicity. Eur J Immunol 37(Suppl 1):S53-S60